Comparison of the Effectiveness of Two Different Surgical Therapeutic Protocols of Peri-implantitis

Implantoplasty Versus Implant Decontamination With Erythritol Air-abrasive Device During Surgical Therapy of Peri-implantitis. Clinical, Radiographic and Microbiological Evaluation. A Randomized Controlled Clinical Study

The purpose of the present study is to compare the 1-year clinical, radiographic and microbiological outcomes and patients' satisfaction following surgical treatment of peri-implantitis after applying two different surface modification methods. Secondarily, analysis and comparison of the microbiological results of implants diagnosed and treated for peri-implantitis with healthy implants will be performed.

Inclusion Criteria:

General Inclusion Criteria:

• Participants ≥ 18 years and ≤ 80 years of age
• Non-smokers based on the patients' self-reported smoking status, defined as patients who had never smoked or had quit smoking at least 2 years ago
• Implants in function for more than 1 year after suprastructure connection

Inclusion Criteria for implants diagnosed with Peri-Implantitis:

• Presence of at least one implant diagnosed with peri-implantitis defined as presence of bleeding on probing and/or suppuration, probing pocket depth ≥6 mm and ≥3 mm of detectable bone loss after initial re-modelling

• Absence of implant mobility

  • in participants with more than one implant, the implant with the worst clinical condition will be studied.

Inclusion Criteria for implants diagnosed with Peri-Implant Health:

• Absence of peri-implant signs of inflammation (redness, swelling)
• Lack of bleeding on probing
• Absence of bone loss beyond crestal bone level changes resulting from initial remodeling, which should not be ≥2 mm

Exclusion Criteria:

• Smokers
• Uncontrolled diabetes mellitus (HBA1c >7)
• Treatment with bisphosphonates
• Needing antibiotic prophylaxis
• Currently pregnant or breast-feeding women
• History of systemic administration of antibiotic treatment during the preceding 3 months
• Systemic conditions that contraindicate treatment
• Use of medications known to induce gingival hyperplasia